Intellia Therapeutics Inc

-1.58 (-2.65%)
Earnings Announcements

Intellia Therapeutics Says Net Loss Was $100.7 Mln For Q2

Published: 08/04/2022 12:06 GMT
Intellia Therapeutics Inc (NTLA) - Cash, Cash Equivalents and Marketable Securities Were $906.9 Million As of June 30, 2022.
Net Loss Was $100.7 Million for Q2 of 2022, Compared to $68.8 Million During Q2 of 2021.
Qtrly Net Loss per Share, Basic and Diluted$1.33.
Q2 Earnings per Share View $-1.31 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $11.43 Million
Adjusted EPS is expected to be -$1.29

Next Quarter Revenue Guidance is expected to be $10.68 Million
Next Quarter EPS Guidance is expected to be -$1.32

More details on our Analysts Page.